Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnau Antolí

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Medicina Clinica|October 4, 2025
Common variable immunodeficiencyXavier Solanich, Arnau Antolí, Laia Alsina
Journal of Clinical Medicine|March 3, 2021
Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory SyndromeXavier Solanich, Miguel Fernández-Huerta, Celeste Basaez, et al.
European Journal of Case Reports in Internal Medicine|June 7, 2024
Severe Gastrointestinal Cytomegalovirus Infection in a Patient Diagnosed with Late Onset Combined ImmunodeficiencyGeorgina Sauqué Pintos, Arnau Antolí Gil, Gemma Rocamora Blanch, et al.
Frontiers in Immunology|April 1, 2025
Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patientsMario Framil, Lydia García-Serrano, Francisco Morandeira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept TrialPierre Malchair, Jordi Giol, Vanesa García, et al.
Journal of Clinical Immunology|May 27, 2025
From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 SeverityArnau Antolí, Gardenia Vargas-Parra, Angels Sierra-Fortuny, et al.
Frontiers in Immunology|May 16, 2022
Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion TherapyArnau Antolí, Gemma Rocamora-Blanch, Mario Framil, et al.
Clinical Immunology (Orlando, Fla.)|April 4, 2025
Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patientsArnau Antolí, José Luis Gómez-Vázquez, Angels Sierra-Fortuny, et al.
Frontiers in Medicine|July 1, 2021
Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled TrialXavier Solanich, Arnau Antolí, Gemma Rocamora-Blanch, et al.
Frontiers in Immunology|August 9, 2021
Genetic Screening for <i>TLR7</i> Variants in Young and Previously Healthy Men With Severe COVID-19Xavier Solanich, Gardenia Vargas-Parra, Caspar I van der Made, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Medicina Clinica|October 4, 2025
Common variable immunodeficiencyXavier Solanich, Arnau Antolí, Laia Alsina
Journal of Clinical Medicine|March 3, 2021
Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory SyndromeXavier Solanich, Miguel Fernández-Huerta, Celeste Basaez, et al.
European Journal of Case Reports in Internal Medicine|June 7, 2024
Severe Gastrointestinal Cytomegalovirus Infection in a Patient Diagnosed with Late Onset Combined ImmunodeficiencyGeorgina Sauqué Pintos, Arnau Antolí Gil, Gemma Rocamora Blanch, et al.
Frontiers in Immunology|April 1, 2025
Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patientsMario Framil, Lydia García-Serrano, Francisco Morandeira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept TrialPierre Malchair, Jordi Giol, Vanesa García, et al.
Journal of Clinical Immunology|May 27, 2025
From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 SeverityArnau Antolí, Gardenia Vargas-Parra, Angels Sierra-Fortuny, et al.
Frontiers in Immunology|May 16, 2022
Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion TherapyArnau Antolí, Gemma Rocamora-Blanch, Mario Framil, et al.
Clinical Immunology (Orlando, Fla.)|April 4, 2025
Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patientsArnau Antolí, José Luis Gómez-Vázquez, Angels Sierra-Fortuny, et al.
Frontiers in Medicine|July 1, 2021
Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled TrialXavier Solanich, Arnau Antolí, Gemma Rocamora-Blanch, et al.
Frontiers in Immunology|August 9, 2021
Genetic Screening for <i>TLR7</i> Variants in Young and Previously Healthy Men With Severe COVID-19Xavier Solanich, Gardenia Vargas-Parra, Caspar I van der Made, et al.
Pageof 2